We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck Gets FDA Approval for Investigational Drug Zinplava
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has approved its pipeline candidate Zinplava (bezlotoxumab, injection 25 mg/mL) for the prevention of Clostridium difficile (C. difficile) infection recurrence. Merck expects to launch Zinplava in the first quarter of 2017.
Note that Zinplava can only be used in combination with an antibacterial drug treatment for the disease.
Zinplava was approved on the basis of two global, double-blind, phase III studies, MODIFY I and MODIFY II. These studies evaluated the use of bezlotoxumab alone or in combination with actoxumab, in comparison to placebo, for the prevention of recurrent CDI in patients receiving standard-of-care antibiotics.
We remind investors that earlier this year, an FDA advisory panel had voted (10 to 5 with one abstention) that the company has provided substantial evidence of the safety and effectiveness of Zinplava for the prevention of C. difficile infection recurrence in patients aged 18 years and older.
The FDA was initially expected to respond on Jul 23, 2016; however, the PDUFA date was extended by three months as the company was asked to submit new data and analyses MODIFY I and MODIFY II that were a part of the Biologics Licensing Application (BLA).
Both the studies met the primary efficacy endpoints. They showed that a single, one-time infusion of bezlotoxumab, along with the standard-of-care CDI antibiotic treatment, significantly reduced the recurrence of the infection compared to the standard of care alone. Bezlotoxumab showed this benefit for more than a 12-week period.
Zinplava was developed jointly by researchers at University of Massachusetts Medical School’s MassBiologics Laboratory and Medarex, a biopharmaceutical company which is now part of Bristol-Myers Squibb Company (BMY - Free Report) . The product was licensed to Merck in 2009.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Exelixis’ loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to 3 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price skyrocketed 105% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Merck Gets FDA Approval for Investigational Drug Zinplava
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has approved its pipeline candidate Zinplava (bezlotoxumab, injection 25 mg/mL) for the prevention of Clostridium difficile (C. difficile) infection recurrence. Merck expects to launch Zinplava in the first quarter of 2017.
Note that Zinplava can only be used in combination with an antibacterial drug treatment for the disease.
Zinplava was approved on the basis of two global, double-blind, phase III studies, MODIFY I and MODIFY II. These studies evaluated the use of bezlotoxumab alone or in combination with actoxumab, in comparison to placebo, for the prevention of recurrent CDI in patients receiving standard-of-care antibiotics.
We remind investors that earlier this year, an FDA advisory panel had voted (10 to 5 with one abstention) that the company has provided substantial evidence of the safety and effectiveness of Zinplava for the prevention of C. difficile infection recurrence in patients aged 18 years and older.
The FDA was initially expected to respond on Jul 23, 2016; however, the PDUFA date was extended by three months as the company was asked to submit new data and analyses MODIFY I and MODIFY II that were a part of the Biologics Licensing Application (BLA).
Both the studies met the primary efficacy endpoints. They showed that a single, one-time infusion of bezlotoxumab, along with the standard-of-care CDI antibiotic treatment, significantly reduced the recurrence of the infection compared to the standard of care alone. Bezlotoxumab showed this benefit for more than a 12-week period.
Zinplava was developed jointly by researchers at University of Massachusetts Medical School’s MassBiologics Laboratory and Medarex, a biopharmaceutical company which is now part of Bristol-Myers Squibb Company (BMY - Free Report) . The product was licensed to Merck in 2009.
MERCK & CO INC Price
MERCK & CO INC Price | MERCK & CO INC Quote
Zacks Rank & Key Picks
Merck currently carries a Zacks Rank #2 (Buy). A couple of favorably placed stocks in the health care sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Exelixis’ loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to 3 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price skyrocketed 105% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>